ZURICH – Roche on April 22 said it will invest US$50 billion (S$65 billion) in the United States over the next five years, in one of the biggest inward investment moves by companies dealing with US President Donald Trump’s tariffs policy.
The Swiss pharma giant said the investment would create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.
Drug makers are announcing investments to counter tariffs by the Trump administration, which is seeking to boost domestic manufacturing.
Roche’s investment follows an announcement by fellow Swiss drug maker Novartis, which earlier this month said it will spend US$23 billion in the US on expanding existing facilities and building new ones.
Roche said its investment will include new research and development sites as well as expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California.
Once all new and expanded manufacturing capacity comes on line, Roche will export more medicines from the US than it imports, the company said.
Roche chief executive Thomas Schinecker said the investment underscored the company’s commitment to the United States.
“Our investments of US$50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world,” he said in a statement. REUTERS
Join ST’s Telegram channel and get the latest breaking news delivered to you.
